These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 26124093)

  • 1. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.
    Pascal KE; Coleman CM; Mujica AO; Kamat V; Badithe A; Fairhurst J; Hunt C; Strein J; Berrebi A; Sisk JM; Matthews KL; Babb R; Chen G; Lai KM; Huang TT; Olson W; Yancopoulos GD; Stahl N; Frieman MB; Kyratsous CA
    Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8738-43. PubMed ID: 26124093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses.
    Dimitrov DS; Jiang S; Ying T; Tseng CT; Zhang L; Yuen KY
    Proc Natl Acad Sci U S A; 2015 Sep; 112(37):E5115. PubMed ID: 26318165
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
    Han HJ; Liu JW; Yu H; Yu XJ
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30513619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient.
    Niu P; Zhang S; Zhou P; Huang B; Deng Y; Qin K; Wang P; Wang W; Wang X; Zhou J; Zhang L; Tan W
    J Infect Dis; 2018 Sep; 218(8):1249-1260. PubMed ID: 29846635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.
    Corti D; Zhao J; Pedotti M; Simonelli L; Agnihothram S; Fett C; Fernandez-Rodriguez B; Foglierini M; Agatic G; Vanzetta F; Gopal R; Langrish CJ; Barrett NA; Sallusto F; Baric RS; Varani L; Zambon M; Perlman S; Lanzavecchia A
    Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10473-8. PubMed ID: 26216974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
    Chen Y; Lu S; Jia H; Deng Y; Zhou J; Huang B; Yu Y; Lan J; Wang W; Lou Y; Qin K; Tan W
    Emerg Microbes Infect; 2017 May; 6(5):e37. PubMed ID: 28536429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.
    Li Y; Wan Y; Liu P; Zhao J; Lu G; Qi J; Wang Q; Lu X; Wu Y; Liu W; Zhang B; Yuen KY; Perlman S; Gao GF; Yan J
    Cell Res; 2015 Nov; 25(11):1237-49. PubMed ID: 26391698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein.
    Widjaja I; Wang C; van Haperen R; Gutiérrez-Álvarez J; van Dieren B; Okba NMA; Raj VS; Li W; Fernandez-Delgado R; Grosveld F; van Kuppeveld FJM; Haagmans BL; Enjuanes L; Drabek D; Bosch BJ
    Emerg Microbes Infect; 2019; 8(1):516-530. PubMed ID: 30938227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
    Kim MH; Kim HJ; Chang J
    PLoS One; 2019; 14(7):e0220196. PubMed ID: 31329652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.
    Tang XC; Marasco WA
    Immunotherapy; 2015; 7(6):591-4. PubMed ID: 26098703
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.
    Kyratsous CA; Olson W; Stahl N
    Proc Natl Acad Sci U S A; 2015 Sep; 112(37):E5116. PubMed ID: 26318164
    [No Abstract]   [Full Text] [Related]  

  • 15. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
    Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G
    J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections.
    Ying T; Li H; Lu L; Dimitrov DS; Jiang S
    Microbes Infect; 2015 Feb; 17(2):142-8. PubMed ID: 25456101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease.
    Tao X; Garron T; Agrawal AS; Algaissi A; Peng BH; Wakamiya M; Chan TS; Lu L; Du L; Jiang S; Couch RB; Tseng CT
    J Virol; 2016 Jan; 90(1):57-67. PubMed ID: 26446606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
    Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
    Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MERS-CoV spike protein: Targets for vaccines and therapeutics.
    Wang Q; Wong G; Lu G; Yan J; Gao GF
    Antiviral Res; 2016 Sep; 133():165-77. PubMed ID: 27468951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein.
    Jiang L; Wang N; Zuo T; Shi X; Poon KM; Wu Y; Gao F; Li D; Wang R; Guo J; Fu L; Yuen KY; Zheng BJ; Wang X; Zhang L
    Sci Transl Med; 2014 Apr; 6(234):234ra59. PubMed ID: 24778414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.